Conquering Chemotherapy-How advances in the management of neutropenia have led to advances in curative therapy. (February 10, 2010)

By Maria G. Essig, MS, ELS If you were to ask the average person—even the most health conscious of your friends—what their neutrophil count is, chances are you would get a blank stare. But as a cancer... Continue Reading

Successful Treatment Means Staying on Schedule (December 2, 2009)

In order to receive the best possible benefit from your cancer therapy, it is important to follow your treatment as your doctor has prescribed. Even if you’re not able to visit your regular treatment... Continue Reading

Dose Intensity Associated with Survival in Non-Hodgkin’s Lymphoma (September 9, 2008)

Relative dose intensity (RDI) remains a key factor in the outcomes of patients with non-Hodgkins lymphoma (NHL). These results have been validated in several multicenter clinical studies. Non-Hodgkin’s... Continue Reading

Neulasta® Deemed Cost-effective for Prevention of Febrile Neutropenia in Breast Cancer Patients (August 15, 2008)

The prophylactic use of Neulasta® (pegfilgrastim) is cost-effective for the prevention of febrile neutropenia in patients undergoing treatment for breast cancer. The details of this study appeared in... Continue Reading

Early Use of Neulasta® Superior to Later Use In Elderly Patients Undergoing Chemotherapy (August 8, 2008)

The use of Neulasta® (pegfilgrastim) after the first cycle of chemotherapy among elderly patients undergoing chemotherapy decreases febrile neutropenia and associated effects compared with its use later... Continue Reading

Prophylactic Neulasta® Reduces Febrile Neutropenia and Early Deaths Among Patients Receiving Chemotherapy (July 31, 2008)

Prophylactic use of Neulasta® (pegfilgrastim) among cancer patients receiving chemotherapy reduces the risk of developing febrile neutropenia and early death. These results were recently published in... Continue Reading

Neulasta® on First Day of Chemotherapy May Be More Convenient for Gynecologic Cancers (March 17, 2008)

The administration of the blood cell growth factor Neulasta® (pegfilgrastim) on the first day of chemotherapy among women with gynecologic cancers may be as effective as and more convenient than second-day... Continue Reading

Neulasta® Reduces Hospitalizations for Febrile Neutropenia in Women with Breast Cancer (October 2, 2007)

According to results presented at the European Cancer Conference (ECCO 14), preventive treatment with Neulasta® (pegfilgastim) improved chemotherapy delivery and reduced the risk of febrile neutropenia... Continue Reading

Early Use of Neulasta Reduces Complications from Neutropenia in Non-Hodgkin’s and Hodgkin’s Lymphomas (January 5, 2007)

According to results recently presented at the 2006 annual meeting of the American Society of Hematology, the use of Neulasta® (pegfilgrastim) during the first courses of chemotherapy significantly reduces... Continue Reading

Neulasta® Safe and Effective for Hodgkin’s Patients Treated with ABVD Chemotherapy (November 7, 2006)

Among Hodgkin’s lymphoma patients treated with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy every two weeks, use of Neulasta® (pegfilgrastim) was safe and allowed most... Continue Reading

Guidelines Address Prevention of Neutropenia (July 13, 2006)

According to updated recommendations from the American Society of Clinical Oncology, use of blood cell growth factors to prevent febrile neutropenia is warranted when risk of febrile neutropenia is 20%... Continue Reading

Fewer Complications Related to Low White Blood Cell Counts Among Patients Treated with Neulasta® in the First Cycle of Chemotherapy (June 7, 2006)

According to the final results of a large clinical trial, giving Neulasta® (pegfilgrastim) to patients undergoing chemotherapy reduces their risk of complications related to low white blood cell counts... Continue Reading

Dose-Dense Therapy for NHL Safely Administered with Support of Neulasta® (April 18, 2006)

Among patients with diffuse large B-cell lymphoma, supportive treatment with Neulasta® (pegfilgrastim) allowed for the safe administration of the dose-dense treatment regimen R-CHOP-14 (rituximab-cyclophosphamide,... Continue Reading

Neulasta® and Aranesp® Prevent Adverse Effects of Dose-Dense Chemotherapy (November 21, 2005)

Treatment with Neulasta® (pegfilgrastim) and Aranesp® (darbepoetin alfa) safely and effectively prevented febrile neutropenia and anemia among women receiving dose-dense chemotherapy for breast cancer,... Continue Reading

Neutropenia Interferes With Symptom Management (August 23, 2005)

Attempts to help patients manage symptoms during cancer treatment may be less effective if patients develop treatment complications such as neutropenia, according to a study published in the journal Cancer. Developing... Continue Reading

Predicting and Preventing Chemotherapy-Induced Neutropenia (August 9, 2005)

According to research findings presented at the 2005 conference of the Multinational Association of Supportive Care in Cancer, several patient and treatment characteristics can be used to identify patients... Continue Reading

Neutropenia Associated with Significant Decline in Quality of Life (July 12, 2005)

According to results recently presented at the 17th MASCC/ISOO International Symposium, patients who experience severe neutropenia suffer a significant decline in quality of life. One of the most common... Continue Reading

One Dose of Neulasta® As Effective As Multiple Doses of Neupogen® after Autologous Transplants (June 17, 2005)

Bone Marrow Transplantation recently published results indicating that one dose of the growth factor Neulasta® (pegfilgrastim) is as effective as multiple doses of Neupogen® (filgrastim) when used following... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS